Tools
Tools
Jeppesen, P B, Pertkiewicz, M, Forbes, A 
ORCID: https://orcid.org/0000-0001-7416-9843, Pironi, L, Gabe, S M, Joly, F, Messing, B, Loth, S, Youssef, N N, Heinze, H and Berghöfer, P
(2013)
Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
Clinical Nutrition, 32 (5).
pp. 713-721.
ISSN 0261-5614
Abstract
Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.
| Item Type: | Article |
|---|---|
| Additional Information: | Copyright © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved. |
| Uncontrolled Keywords: | adult,aged,cost of illness,double-blind method,drinking,drug resistance,gastrointestinal agents,glucagon-like peptide 2,humans,injections, subcutaneous,intestinal diseases,intestine, small,middle aged,organ dysfunction scores,organ size,parenteral nutrition, home,peptides,quality of life,receptors, glucagon,short bowel syndrome |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology Faculty of Medicine and Health Sciences > Research Groups > Nutrition and Preventive Medicine |
| Depositing User: | Pure Connector |
| Date Deposited: | 06 Aug 2014 10:48 |
| Last Modified: | 20 Oct 2022 19:31 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/49795 |
| DOI: | 10.1016/j.clnu.2013.03.016 |
Actions (login required)
 |
View Item |